MARK2 Antibody #9118
- WB
Supporting Data
REACTIVITY | H M R |
SENSITIVITY | Endogenous |
MW (kDa) | 78, 82 |
SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys430 of human MARK2. Antibodies were purified by protein A and peptide affinity chromatography.
Background
Microtubule associated proteins regulate the stability of microtubules and control processes such as cell polarity/differentiation, neurite outgrowth, cell division and organelle trafficking (1). The MARK (MAP/microtubule affinity-regulating kinases) family (MARK1-4) of serine/threonine kinases was identified based on their ability to phosphorylate microtubule-associated proteins (MAPs) including tau, MAP2 and MAP4 (2-6). MARK proteins phosphorylate MAPs within their microtubule binding domains, causing dissociation of MAPs from microtubules and increased microtubule dynamics (2-4). In the case of tau, phosphorylation has been hypothesized to contribute to the formation of neurofibrillary tangles observed in Alzheimer's disease. Overexpression of MARK leads to hyperphosphorylation of MAPs, morphological changes and cell death (4). The tumor suppressor kinase LKB1 phosphorylates MARK and the closely related AMP-kinases within their T-loops, leading to increased activity (7).
MARK2 (4), also termed as Par-1 (8) and EMK1 (9), contributes to cellular polarity, cell cycle progression, microtuble dynamics, and neurite outgrowth. The MARK2 gene encodes at least two alternatively spliced isoforms that are co-expressed in various cell lines (10). Substrates of MARK2 include microtubule associated protein (MAPs), tau, histone deacetylases (11), and Rab11-FIP2 (12). Knockout studies suggest that MARK2 plays an essential role in immune system function (13), glucose homeostasis (14), and learning and memory (15).
- Drubin, D.G. and Nelson, W.J. (1996) Cell 84, 335-44.
- Illenberger, S. et al. (1996) J Biol Chem 271, 10834-43.
- Drewes, G. et al. (1995) J Biol Chem 270, 7679-88.
- Drewes, G. et al. (1997) Cell 89, 297-308.
- Kato, T. et al. (2001) Neoplasia 3, 4-9.
- Trinczek, B. et al. (2004) J Biol Chem 279, 5915-23.
- Lizcano, J.M. et al. (2004) EMBO J 23, 833-43.
- Guo, S. and Kemphues, K.J. (1995) Cell 81, 611-620.
- Inglis, J.D. et al. (1993) Mamm. Genome 4, 401-403.
- Espinosa, L. and Navarro, E. (1998) Cytogenet. Cell Genet. 81, 278-282.
- Dequiedt, F. et al. (2006) Mol. Cell. Biol. 26, 7086-7102.
- Ducharme, N.A. et al. (2006) Mol. Biol. Cell 17, 3625-3637.
- Hurov, J.B. et al. (2001) Mol. Cell. Biol. 21, 3206-3219.
- Hurov, J.B. et al. (2007) Proc. Natl. Acad. Sci. USA 104, 5680-5685.
- Segu, L. et al. (2008) Neurobiol. Aging 29, 231-240.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.